Prognostic value and therapeutic potential of the cuproptosis-related gene LOXL2 in thyroid cancer

Abstract Four dysregulated cuproptosis-related genes (MT1A, MT1F, LOXL2, MT1M) are identified in THCA via TCGA-THCA cohort analysis. High-risk THCA patients (CRG risk model) exhibit lower immune scores, poorer overall survival, and abnormal metabolic pathways. LOXL2 exhibits the strongest prognostic association among the identified dysregulated cuproptosis-related genes in THCA. LOXL2 knockdown inhibits THCA cell proliferation, migration and invasion; cuproptosis inducers demonstrate significant anti-tumour effects. LOXL2 represents a novel cuproptosis-related prognostic biomarker and potential therapeutic target for THCA. Article type: Research Article